Atogepant, marketed under the name Qulipta, is a medication primarily used for the preventive treatment of migraines in adults. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists. The purpose of Atogepant is to reduce the frequency, severity, and duration of migraines by blocking the activity of CGRP, a neuropeptide involved in the initiation and progression of migraines. By targeting CGRP, Atogepant helps to alleviate the debilitating symptoms associated with migraines and improve the quality of life for individuals suffering from this condition. It is important to note that Atogepant should not be used for the treatment of acute migraine attacks.
This mind map was published on 20 October 2023 and has been viewed 92 times.